Update on immunotherapy for non-muscle invasive transitional cell carcinoma of the bladder | Urology News
Avelumab (anti-PD-L1) in platinum-resistant/refractory ovarian cancer: JAVELIN Ovarian 200 Phase III study design | Future Oncology
Avelumab in gastric cancer | Immunotherapy
An evaluation of avelumab for the treatment of genitourinary tumors
Mechanism of action of nivolumab. | Download Scientific Diagram
Current and Future Perspectives of PD-1/PDL-1 Blockade in Cancer Immunotherapy
Cancers | Free Full-Text | Landscape and Future Perspectives of Immunotherapy in Neuroendocrine Neoplasia | HTML
Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations | SpringerLink
The Impact of Immune Checkpoint-Inhibitors Therapy in Urinary Bladder Cancer
Avelumab's dual mechanism of action. Avelumab is a human IgG1... | Download Scientific Diagram
Immune checkpoint inhibitors of PD-L1 as cancer therapeutics | Journal of Hematology & Oncology | Full Text
PD-L1 inhibition with avelumab for metastatic Merkel cell carcinoma. - Abstract - Europe PMC
Anti–Programmed Cell Death 1/Ligand 1 (PD-1/PD-L1) Antibodies for the Treatment of Urothelial Carcinoma: State of the Art and Future Development - Clinical Genitourinary Cancer
Immunotherapy in Nonmelanoma Skin Cancer - ScienceDirect
Immunotherapy for HER2-positive breast cancer: recent advances and com | BCTT
Prognostic significance of tumor immune microenvironment and immunotherapy: Novel insights and future perspectives in gastric cancer
Overview of immune pathways and actions of checkpoint inhibitors. The... | Download Scientific Diagram
Avelumab: clinical trial innovation and collaboration to advance anti-PD-L1 immunotherapy - Annals of Oncology
Drug resistance in cancer immunotherapy: new strategies to improve checkpoint inhibitor therapies
Frontiers | Incidence of Immune-Related Adverse Events with Program Death Receptor-1- and Program Death Receptor-1 Ligand-Directed Therapies in Genitourinary Cancers | Oncology
Previously Treated Advanced UC | BAVENCIO® (avelumab) HCP | Safety Info
Avelumab's dual mechanism of action. | Download Scientific Diagram
Note for reviewers
Merck Pfizer Alliance Strategy in gynecologic oncology
Mechanism of Action | BAVENCIO® (avelumab) HCP | Safety Info
Pharmacokinetic/pharmacodynamic relationship of therapeutic monoclonal antibodies used in oncology: Part 2, immune checkpoint inhibitor antibodies - European Journal of Cancer
